The path for brilacidin is getting better and bett
Post# of 72440
Agree that todays PR isn't a market mover. We've been seeing OM data pr's for a while, The PR was written very well though imo. A good read that puts all the CDA's on notice that we're very close.
So, who wants to meet with the FDA with us?
We shall see. Might even happen before I get my pool open in a couple weeks.
$IPIX